Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Ilan R. Kirsch, Juliana Craig, Frederick L. Locke, Michael D. Jain, Allison P. Jacob, Lik Wee Lee, Jay Y. Spiegel, Matthew J. Frank, Ali Bukhari, Gursharan K. Claire, David B. Miklos, Katherine A. Kong, Aaron P. Rapoport, Erin Dean, Nasheed Hossain, Chelsea D. Mullins, Crystal L. Mackall, Saurabh Dahiya
Publikováno v:
J Clin Oncol
PURPOSE Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic
Autor:
Jawad Malik, Saurabh Dahiya, Gabriela Sanchez-Petitto, Preeti Chandra, A. Haririan, Matthew R. Weir, Aaron P. Rapoport, Cinthia B. Drachenberg, Jonathan Bolanos
Publikováno v:
Clinical Nephrology. Case Studies
Use of granulocyte colony-stimulating factor (G-CSF) has been associated with side effects including reports of acute glomerulonephritis (GN), almost all of which have been immune complex associated. There is one prior report of pauci-immune GN in a
Autor:
Abhinav Deol, Amanda F. Cashen, N. Nora Bennani, Khoan Vu, Michael D. Jain, David B. Miklos, Sattva S. Neelapu, Brian T. Hill, Jason R. Westin, Julie M. Vose, Alison R. Sehgal, Julio C. Chavez, Aaron P. Rapoport, Lazaros J. Lekakis, Andre Goy, Patrick M. Reagan, Javier Munoz, Joseph P. McGuirk, Loretta J. Nastoupil, Lei Feng, Olalekan O. Oluwole, Saurabh Dahiya, Jay Y. Spiegel, Frederick L. Locke, Charalambos Andreadis, Yi Lin, Matthew A. Lunning, Armin Ghobadi
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed b
Autor:
Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres
Publikováno v:
Neuro Oncol
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associat
Autor:
Joseph A. Fraietta, Edward A. Stadtmauer, Aaron P. Rapoport, Bruce L. Levine, Wei-Ting Hwang, Dan T. Vogl, Adam D. Cohen, Megan M. Davis, Carl H. June, Adam Waxman, Don L. Siegel, Alfred L. Garfall, Michael C. Milone, Ehren K. Dancy, J. Joseph Melenhorst
Publikováno v:
Blood Advances. 3:2812-2815
Key points T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory
Autor:
Nicole M. Glynn, Kim G. Hankey, Erica Vander Mause, Forat Lutfi, Stephanie Avila, Djordje Atanackovic, Hanan Alkhaldi, Saurabh Dahiya, Aaron P. Rapoport, Heather D. Mannuel, Tim Luetkens, Gabriela Sanchez-Petitto, John W Baddley, Nancy M. Hardy
Publikováno v:
Vaccines
Vaccines, Vol 9, Iss 737, p 737 (2021)
Vaccines, Vol 9, Iss 737, p 737 (2021)
Patients after autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) are at an increased risk of COVID-19-related morbidity and mortality, compounded by an immune system weakened by the underlying malignancy and prior treatments. Al
Autor:
Adam M. Petrich, Koen van Besien, Justin Kline, Krishna Rao, Sreenivasa Nattam, Ajay Major, Amy S. Kimball, Aaron P. Rapoport, Kenneth J. Cohen, Bethany G. Sleckman, Sonali M. Smith, Theodore Karrison, Paul A. S. Fishkin
Publikováno v:
Haematologica. 107(7)
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the
Autor:
Gwendolyn K. Binder, Thomas H. Faitg, Karen Chagin, Elliot Norry, Jean-Marc Navenot, Edward A. Stadtmauer, Trupti Trivedi, Karen Dengel, Aaron P. Rapoport, Daniel E. Lowther, Rafael G. Amado, Malini Iyengar, Luca Melchiori, Ashraf Badros, Ruoxi Wang
Publikováno v:
Blood Advances. 3:2022-2034
This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM) evaluated the safety and activity of autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) that recognizes a peptide shared by cancer a
Autor:
Ashkan Emadi, Zeba N. Singh, Mehmet H. Kocoglu, Aaron P. Rapoport, Vu H. Duong, Maria R. Baer, Ashraf Badros, Rima Koka, Ying Zou, Noa G. Holtzman
Publikováno v:
Leukemia & Lymphoma. 60:3577-3580
Outcomes and life expectancy for patients with multiple myeloma (MM) have improved substantially over the last two decades with advancements in therapy, including autologous stem cell transplantati...
Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy
Autor:
Saurabh Dahiya, Perry K. Richardson, Khushali Jhaveri, Aaron P. Rapoport, Ilana Schlam, Monica Peravali, Noa G. Holtzman, Vera Malkovska
Publikováno v:
Blood Adv
Key Points CAR T-cell therapy was safe and effective in a DLBCL patient with coexisting autoimmune neuropathy. CD19 CAR T-cell therapy may control refractory autoantibodies and monoclonal gammopathies.